UCL Business
banner
uclb.bsky.social
UCL Business
@uclb.bsky.social
Our role is to nurture technology from UCL, its collaborators and associated hospitals to market, transforming ideas into enterprise with global impact, whilst bringing revenue back to the university to fund more pioneering work.
... model enables rapid, fair deal formation with 90%+ equity for founders of non-patentable intellectual property (IP).

Remind yourself of USIT and how it benefits research commercialisation 👉 www.uclb.com/2024/05/20/u...
UCLB and UCL join leading university technology transfer offices to welcome new guidelines on forming software spinout businesses
A new guide designed to accelerate and support the development of a new generation of innovative software spinouts has been launched by a leading group of universities with backing of major investors.
www.uclb.com
November 10, 2025 at 11:46 AM
... to the expert workshop on this guidance last week, discussing how to attract investment while protecting institutional interests and be financially sustainable.

She shared more about the UK’s experience through the USIT Guide, our founder-friendly equity deals: our Portico Ventures

2/
November 10, 2025 at 11:46 AM
... even AZ and Merck have chosen to retreat.

The cutting-edge tech & life-changing research coming out of institutions like UCL could help realise the first homegrown trillion-pound company.

There is plenty to be excited about - read the article here (p39): onenucleus.com/publications

2/
Publications | One Nucleus
onenucleus.com
November 7, 2025 at 10:33 AM
Previously, he was focused on producing excellent academic research, but now - after licensing his own work - Stefan is keen to patent technologies and see them used in real-world applications, alongside writing high quality, impactful papers.

See you at our next IO Converse in January?

2/
November 4, 2025 at 11:30 AM
... one that is already offering hope to blood cancer patients.

Emily Henders, a 37-year-old biology teacher & mum of two, shared her decision to participate with Sky News.

We look forward to seeing how this trial develops! 👏

Read more: www.uclb.com/2025/10/24/a...

3/
Autolus breaks new ground: first MS patient dosed in obe-cel Phase 1 trial
UCLB spinout Autolus Therapeutics has announced a major milestone: the first patient dosed in its Phase 1 BOBCAT trial of obecabtagene autoleucel (obe-cel) for progressive multiple sclerosis (PMS).
www.uclb.com
October 28, 2025 at 3:17 PM
This ‘one-time’ treatment sees patients receive an infusion of their own T-cells, modified to recognise and hunt down rogue elements in their immune system, which are the underlying cause of multiple sclerosis.

The beginning of the trial marks a significant expansion of the therapy platform...

2/
October 28, 2025 at 3:17 PM
The report also noted that UCL has 'a proportionally high number of spinouts' in the government's priority sectors.

Read more about these stats: www.uclb.com/2025/10/21/u...
UCL spinouts amongst the top for investment in the UK
UCL has cemented its position as a powerhouse for innovation, with its spinouts being amongst the top for equity investment value in 2024, according to Beauhurst.
www.uclb.com
October 21, 2025 at 1:51 PM
Ana said:
> 𝗘𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲: evaluating ideas, shaping business plans, offering IP or licensing advice
> 𝗡𝗲𝘁𝘄𝗼𝗿𝗸𝘀: connecting founders with advisers & collaborators
> 𝗙𝗶𝗻𝗮𝗻𝗰𝗲: helping with grant applications, translational funding, providing PoC funds to test / prototype ideas

and more were vital.
October 17, 2025 at 8:54 AM
UCLB is proud to call the Euston Knowledge Quarter home and be leading the momentum with:

- 95 active spinouts across healthcare, AI, and tech
- Over £3 billion raised in external investment over the last five years
- and the creation of 2,400 jobs.
September 30, 2025 at 8:27 AM
The trajectory of this possibility is incredibly exciting:
adding £3.5 billion to the economy, creating 30,000 new jobs, and driving breakthroughs in cancer, Alzheimer’s, sustainable energy & more.

Such growth would exceed that of Boston's Kendall Sqaure...!
September 30, 2025 at 8:27 AM
... in introducing an innovative protein pore into ONT's devices.

Dr Barny Cox, Senior Business Manager at UCLB, will chair the session on:

📅 16 October 2025
🕑 12.30pm-2pm (light lunch provided)
📍 90 Tottenham Court Road

Register your place here: www.eventbrite.co.uk/e/io-convers...

2/
IO Converse:
Revolutionising biotechnology through nanopore sequencing
www.eventbrite.co.uk
September 29, 2025 at 12:57 PM
... of development of many of our highly successful spinouts across a multitude of disciplines.

Take a look at our stats on PoC funding or find out more about how it's helped UCL spinouts: www.uclb.com/2025/09/23/t...

3/3
September 23, 2025 at 1:55 PM
Both were nominated by UCLB.

PoC funding has been a vital part of the commercialisation landscape at UCL for almost 20 years.

It helps bridge the funding gap between research grants and investment, supporting the early stages...

2/3
September 23, 2025 at 1:55 PM